Nine Masts Capital’s Legend Biotech LEGN Stock Holding History

Nine Masts Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,900	Closed	-$49.1K	–	184
2024 Q3	$49.1K	Buy	+40,900	New	+$2.18M	0.02%	102

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nine Masts Capital's LEGN Position: Q1 2025 in Review

Nine Masts Capital sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 38,466 shares — an estimated $1.25M sold.

Nine Masts Capital first reported a position in LEGN in Q3 2024 and held it in 2 quarters. The position peaked at $1.25M in Q4 2024. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

Nine Masts Capital reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
Nine Masts Capital sold 38,466 Legend Biotech shares in Q1 2025, an estimated $1.25M.
Nine Masts Capital first reported a position in Legend Biotech in Q3 2024 and held it in 2 quarters.
Nine Masts Capital's Legend Biotech position peaked at $1.25M in Q4 2024.
208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Nine Masts Capital's 13F filing for Q1 2025, filed 13 May 2025.